Collagen proline hydroxylase inhibitors are primarily used in research and therapeutic contexts to modulate collagen synthesis and degradation. By inhibiting the enzyme responsible for hydroxylating proline residues in collagen, these compounds can influence the stability and maturation of collagen fibers. This mechanism is particularly relevant in studies focused on fibrosis, where excessive collagen deposition leads to tissue scarring and organ dysfunction. In such cases, these inhibitors help reduce collagen production, potentially mitigating fibrotic progression. Additionally, they are explored in cancer research, as collagen remodeling plays a role in tumor microenvironment regulation and metastasis. Their application extends to dermatology, where controlling collagen synthesis can impact skin aging and wound healing processes. Overall, these inhibitors serve as valuable tools in understanding and managing diseases associated with collagen dysregulation.